<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902184</url>
  </required_header>
  <id_info>
    <org_study_id>IPH4102-201</org_study_id>
    <secondary_id>2018-003969-33</secondary_id>
    <nct_id>NCT03902184</nct_id>
  </id_info>
  <brief_title>IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma</brief_title>
  <acronym>TELLOMAK</acronym>
  <official_title>TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-cohort, and multi-center phase II study, which evaluates the
      clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single
      agent, and in patients with peripheral T-cell lymphoma in combination with gemcitabine and
      oxaliplatin chemotherapy (GEMOX)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Using the Olsen (2011, JCO) criteria (Cohorts 1-3), or Lugano Criteria (Cohorts 4-5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)</measure>
    <time_frame>From first dose until study completion, an expected average of 2 years</time_frame>
    <description>patients with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) (Cohorts 1-3)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>Using the Skindex29 questionnaire to assesse the effects of skin disease on quality of life in three domains: Symptoms, Emotions, and Functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pruritus (Cohorts 1-3)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>Using Visual Analog Scale (VAS) for prutitus assessment: From 0 = No pruritus to 10 = Pruritus as bad as it could possibly be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR using central review (Cohort 1)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Using the Olsen (2011, JCO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR lasting at least 4 months (ORR4) (Cohorts 1-3)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Using the Olsen (2011, JCO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters : Maximum Plasma Concentration of IPH4102 alone (Cohorts1-3) or in combination with GEMOX (Cohorts 4 and 5);</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Maximum Plasma Concentration (Cmax) (W1, W5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters :Trough Concentration of IPH4102 alone (Cohorts1-3) or in combination with GEMOX (Cohorts 4 and 5);</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Trough Concentration (Ctrough) every 8 or 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IPH4102 alone (Cohorts1-3) or in combination with GEMOX (Cohorts 4 and 5);</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>A serum sample will be collected at the specified time points for evaluation of anti-drug antibodies (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of treatment on minimal residual disease (MRD) (Cohort 1).</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>A whole blood sample will be collected at the specified time points for evaluation of MRD</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lymphoma, T-Cell</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Lymphoma, T-Cell, Peripheral</condition>
  <condition>Mycosis Fungoides/Sezary Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Relapsed/refractory Sezary Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Peripheral T-cell lymphoma, KIR3DL2 expressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
GEMOX will be administered every 2 weeks for a maximum of 8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Peripheral T-cell lymphoma, KIR3DL2 non-expressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
GEMOX will be administered every 2 weeks for a maximum of 8 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPH4102</intervention_name>
    <description>Patients will receive a flat dose of 750mg</description>
    <arm_group_label>Cohort 1: Relapsed/refractory Sezary Syndrome</arm_group_label>
    <arm_group_label>Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing</arm_group_label>
    <arm_group_label>Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing</arm_group_label>
    <arm_group_label>Cohort 4: Peripheral T-cell lymphoma, KIR3DL2 expressing</arm_group_label>
    <arm_group_label>Cohort 5: Peripheral T-cell lymphoma, KIR3DL2 non-expressing</arm_group_label>
    <other_name>lacutamab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Oxaliplatin</intervention_name>
    <description>Patients will receive a dose ranging from 800-1000 mg/m2 of gemcitabine and 75-100mg/m2 of oxalipatin, according to local practice .</description>
    <arm_group_label>Cohort 4: Peripheral T-cell lymphoma, KIR3DL2 expressing</arm_group_label>
    <arm_group_label>Cohort 5: Peripheral T-cell lymphoma, KIR3DL2 non-expressing</arm_group_label>
    <other_name>GEMOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Cohort 1:

          1. Patients with relapsed/refractory Sezary Syndrome (SS) who have received at least 2
             prior systemic therapies;

          2. Prior treatment with mogamulizumab;

          3. Patients should have blood stage B2 at screening based on central evaluation by flow
             cytometry;

          4. Feasibility of obtaining at least 1 skin biopsy at screening.

             - Cohorts 2 and 3:

          5. Patients with stage IB to IV Mycosis fongoïdes (MF);

          6. KIR3DL2 expression (Cohort 2) or non-expression (Cohort 3) by immunohistochemistry
             performed centrally on at least one skin lesion;

          7. Patients should have received at least 2 prior systemic therapies that may include
             biological agents;

          8. Feasibility of obtaining at least 1 skin biopsy at screening;

          9. Adequate baseline laboratory data: Hematology: CD4+ T-cells ≥ 200/μL.

             - Cohorts 4 and 5:

         10. Patients with relapsed/refractory Peripheral T Cell Lymphoma (PTCL) of the following
             subtypes:

             PTCL-NOS, angioimmunoblastic T-cell lymphoma (AITL), or anaplastic large cell lymphoma
             (ALCL);

         11. KIR3DL2 expression (Cohort 4) or non-expression (Cohort 5) by immunohistochemistry
             performed centrally on at least one involved lymph node;

         12. Patients should have received at least 1 prior systemic therapy including an
             anthracycline-based chemotherapy. Patients who are not eligible for treatment with
             anthracycline based therapy are eligible for inclusion provided that they were treated
             with at least one prior systemic therapy;

         13. Presence of at least 1 target lesion on PET/CT scan at screening;

         14. Feasibility of obtaining 1 lymph node biopsy at screening.

             - All cohorts:

         15. Male or Female, at least 18 years of age;

         16. ECOG performance status ≤2;

         17. The patient must have a minimum wash-out period of 4 weeks between the last dose of
             prior systemic therapy (8 weeks for biological agents) and the first dose of IPH4102

         18. Patients should have recovered from all adverse events related to prior therapy to ≤
             grade 1;

         19. Adequate baseline laboratory data

         20. Women of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy
             test result within seven days from start of treatment;

         21. Women of childbearing potential and all men (and their female partners of childbearing
             potential) who are sexually active must agree to use adequate method of contraception
             at study entry, during treatment and for at least 9 months (270 days) following the
             last dose of study drug.

        Exclusion Criteria:

        - Cohorts 1 to 3:

          1. Patients with evidence of large cell transformation (LCT) based on central histologic
             evaluation.

             - Cohorts 4 and 5:

          2. Prior administration of gemcitabine and/or oxaliplatin;

          3. Presence of grade 2 neurotoxicity or higher.

             - All Cohorts:

          4. Known central nervous system (CNS) lymphoma;

          5. Prior administration of lacutamab/IPH4102;

          6. Concomitant administration of radiotherapy or systemic anti-cancer therapy including
             but not restricted to: chemotherapy, biological agents or immunotherapy;

          7. Autologous stem cell transplantation less than 3 months prior to enrollment;

          8. Prior allogenic transplantation;

          9. Concomitant corticosteroid use, systemic or topical. However, stable dosage of topical
             steroids (maximum strength Class III according to World Health Organization (WHO)
             Classification of Topical Corticosteroids) and/or systemic steroids (≤10 mg prednisone
             equivalent/day) are allowed, if patient has been on a stable dose for at least 4 weeks
             prior to treatment start;

         10. Patients who have undergone major surgery ≤ 4 weeks prior to study entry;

         11. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral,
             bacterial, or fungal infection;

         12. Patients who have active Hepatitis B or C virus infection;

         13. Patients who are known to be HIV-positive;

         14. Patients with a history of other malignancies during the past 5 years apart from the
             disease subject of this study. The following are exempt from the five-year limit:
             non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer,
             biopsy-proven cervical intraepithelial neoplasia or cervical carcinoma in situ;

         15. Pregnant or breastfeeding women;

         16. Patients with congestive heart failure, Class III or IV, by New York Heart Association
             (NYHA) criteria;

         17. Patients with known active autoimmune disease;

         18. Patients with any serious underlying medical condition that would impair their ability
             to receive or tolerate the planned treatment and/or comply with study protocol;

         19. Patients with dementia or altered mental status that would
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hatem A Azim, MD,PhD</last_name>
    <phone>+33484903084</phone>
    <email>Hatem.ABDELAZIM@innate-pharma.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Paiva</last_name>
    <phone>+33484903084</phone>
    <email>christine.paiva@innate-pharma.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130-4899</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie BEYLOT-BARRY, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François LEMMONIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MORTIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane DALLE, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DEREURE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis Service d'Onco-Hématologie</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis Service de Dermatologie</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine BAGOT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri ADAMSKI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology, Ruhr-University Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rudolf STADLER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia Lorenzo e Ariosto Seragnoli</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo FAVA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia SCARISBRICK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK - Christie Hospital Foundation NHS Trust - Dept of Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim ILLIDGE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

